Shares of I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, plummeted 5.30% during intraday trading on Monday, following the announcement of new appointments to its Board of Directors and Scientific Advisory Board, as well as the formation of a Research and Development Committee.

The company revealed early Monday that it had appointed Dr. Robert Lenz, Ms. Xin Liu, and Dr. Sean Cao to its Board of Directors. Additionally, I-Mab announced the formation of a Research and Development Committee and the appointment of Dr. Ken Takeshita to its Scientific Advisory Board. While these changes were positioned as enhancements to the company's expertise and strategic focus, investors appeared to react negatively to the news.

The sharp decline in I-Mab's stock price suggests that the market may be uncertain about how these leadership changes will impact the company's future direction and performance. Investors might be concerned about potential shifts in strategy or execution that could result from the new appointments. Despite the company's emphasis on strengthening its R&D capabilities and board expertise, the market's immediate reaction indicates a level of skepticism or caution among shareholders.